signal/raiseTrack rounds
Series AHealthtech & bio · Vilnius

Biomatter raises $18m Series A led by Astanor to scale AI enzyme design

The Vilnius company, whose customers include AstraZeneca, BASF and Sanofi, will build a 2,000 square-metre design and testing lab and grow its US business.

s/rFunding deskEurope · 2 min read

Biomatter, a Lithuanian company that designs custom enzymes with computational models, raised an oversubscribed $18m Series A round led by Astanor, it announced on 12 November 2026.

Existing investors UVC Partners, Inventure and Metaplanet also took part, and UVC Partners said it increased its investment in this round. The company did not disclose a valuation or how much it has raised in total.

Biomatter was founded in 2018 and is based in Vilnius. Laurynas Karpus is its chief executive and a co-founder.

“Our goal is to make a custom enzyme as easy to order as a catalog product, including for reactions that don’t have one today.”Laurynas Karpus, CEO and co-founder, Biomatter

What Biomatter does

Enzymes are proteins that speed up chemical reactions, and industry uses them to make medicines, food ingredients and laboratory reagents. Most commercial enzymes begin as natural ones that are then modified, a process that can take months or years.

Biomatter starts instead from the reaction a customer needs and designs an enzyme to carry it out, combining computational models with laboratory tests. Each project adds experimental results to its own dataset of characterised enzymes, which the company says makes later projects faster and more accurate. Its founders published early work on using generative models to produce working enzymes unlike those found in nature in Nature Machine Intelligence in 2021.

One of its designs is in Thermo Fisher Scientific's Invitrogen SuperScript V reverse transcriptase, an enzyme used to turn RNA into DNA in molecular biology and mRNA research. Biomatter worked with Thermo Fisher to make it more resistant to oxidation. In another project it designed a methylase for mRNA vaccine production that works without S-adenosylmethionine (SAM), an expensive additive that natural methylases need.

Customers and investors

The company says it has delivered more than 50 custom enzymes to more than 25 enterprise customers in Europe, the United States and Japan, including AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos. About half of its customers are in the US, and several have moved from a single project to multi-year programmes covering several enzymes. The Next Web noted that it had not independently verified the customer figures.

Harry Briggs, a partner at Astanor, said work in the field had been held back because models could only be trained on data from enzymes that exist in nature, and that Biomatter had spent years producing data beyond that. Oliver Schoppe, a partner at UVC Partners, said most companies applying AI to biology were still trying to show it works, while Biomatter's enzymes were already in products on sale.

What the money is for

The round will pay for a 2,000 square-metre (about 21,500 sq ft) design and testing facility in Vilnius, due to open in 2027, which will bring more of the design and lab work in-house. Biomatter says its projects now take weeks, against months or years for conventional enzyme programmes, and it wants the new site to cut that to days.

The company will also enlarge its commercial team and its presence in the US, and keep investing in its computational platform and enzyme dataset.

The funding so far

Biomatter's previous round was a €6.5m (about $7.1m) seed round in August 2024, jointly led by Inventure and UVC Partners, according to an announcement by Practica Capital. Practica Capital and Metaplanet, both existing investors at the time, also joined that round.

Company website: biomatter.ai